OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluation of clinical benefits of treatments for Alzheimer's disease
Kathy Liu, Sebastian Walsh, Carol Brayne, et al.
The Lancet Healthy Longevity (2023) Vol. 4, Iss. 11, pp. e645-e651
Open Access | Times Cited: 18
Kathy Liu, Sebastian Walsh, Carol Brayne, et al.
The Lancet Healthy Longevity (2023) Vol. 4, Iss. 11, pp. e645-e651
Open Access | Times Cited: 18
Showing 18 citing articles:
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 559
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 559
The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease
Marie Sarazin, Julien Lagarde, I. Haddad, et al.
Nature Aging (2024) Vol. 4, Iss. 6, pp. 761-770
Closed Access | Times Cited: 12
Marie Sarazin, Julien Lagarde, I. Haddad, et al.
Nature Aging (2024) Vol. 4, Iss. 6, pp. 761-770
Closed Access | Times Cited: 12
Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease
Eva Matt, Michael Mitterwallner, Sonja Radjenovic, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2459170-e2459170
Open Access | Times Cited: 1
Eva Matt, Michael Mitterwallner, Sonja Radjenovic, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2459170-e2459170
Open Access | Times Cited: 1
Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives
Sebastian Walsh, Richard L. Merrick, Richard Milne, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6639-6646
Open Access | Times Cited: 7
Sebastian Walsh, Richard L. Merrick, Richard Milne, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6639-6646
Open Access | Times Cited: 7
Are lecanemab and donanemab disease‐modifying therapies?
Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6659-6661
Open Access | Times Cited: 6
Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6659-6661
Open Access | Times Cited: 6
A philosophy of science approach to the amyloid hypothesis of Alzheimer's disease
Timothy Daly
European Journal of Neuroscience (2024) Vol. 60, Iss. 5, pp. 4707-4722
Open Access | Times Cited: 4
Timothy Daly
European Journal of Neuroscience (2024) Vol. 60, Iss. 5, pp. 4707-4722
Open Access | Times Cited: 4
Challenges in a Biological Definition of Alzheimer Disease
Jemma Hazan, Kathy Liu, Harry Costello, et al.
Neurology (2024) Vol. 103, Iss. 9
Closed Access | Times Cited: 4
Jemma Hazan, Kathy Liu, Harry Costello, et al.
Neurology (2024) Vol. 103, Iss. 9
Closed Access | Times Cited: 4
Communicating scientific evidence: drugs for Alzheimer's disease as a case study
Kasper P. Kepp, Poul F. Høilund‐Carlsen, Ioana A. Cristea, et al.
Current Medical Research and Opinion (2025), pp. 1-15
Closed Access
Kasper P. Kepp, Poul F. Høilund‐Carlsen, Ioana A. Cristea, et al.
Current Medical Research and Opinion (2025), pp. 1-15
Closed Access
Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's disease
Kathy Liu, Stephen Senn, Robert Howard
Alzheimer s & Dementia (2025)
Open Access
Kathy Liu, Stephen Senn, Robert Howard
Alzheimer s & Dementia (2025)
Open Access
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
Madia Lozupone, Vittorio Dibello, Antonio Daniele, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Madia Lozupone, Vittorio Dibello, Antonio Daniele, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Minimal clinically important differences for treatment of hallucinations in Parkinson’s disease and dementia with Lewy bodies
Suzanne Reeves, Josef Mahdi, Matthew Appleby, et al.
Psychological Medicine (2025) Vol. 55
Closed Access
Suzanne Reeves, Josef Mahdi, Matthew Appleby, et al.
Psychological Medicine (2025) Vol. 55
Closed Access
Pharmacologic and Nutritional Interventions for Early Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Baoqi Zeng, Chunbian Tang, Junjian Wang, et al.
Journal of Alzheimer s Disease (2024) Vol. 99, Iss. 4, pp. 1173-1186
Open Access | Times Cited: 3
Baoqi Zeng, Chunbian Tang, Junjian Wang, et al.
Journal of Alzheimer s Disease (2024) Vol. 99, Iss. 4, pp. 1173-1186
Open Access | Times Cited: 3
Measuring our language about anti-amyloid antibodies in Alzheimer’s disease: Technical, theoretical, and lay language considerations
Timothy Daly, Markku Kurkinen
Clinical Neurology and Neurosurgery (2024) Vol. 241, pp. 108314-108314
Closed Access | Times Cited: 2
Timothy Daly, Markku Kurkinen
Clinical Neurology and Neurosurgery (2024) Vol. 241, pp. 108314-108314
Closed Access | Times Cited: 2
Lecanemab’s benefits are too small and uncertain
Robert Howard
BMJ (2024), pp. q2044-q2044
Closed Access | Times Cited: 2
Robert Howard
BMJ (2024), pp. q2044-q2044
Closed Access | Times Cited: 2
A combination of Δ9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer's disease
Núria Sánchez-Fernández, Laura Gómez-Acero, Anna Castañé, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 5, pp. e00439-e00439
Open Access | Times Cited: 1
Núria Sánchez-Fernández, Laura Gómez-Acero, Anna Castañé, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 5, pp. e00439-e00439
Open Access | Times Cited: 1
A combination of Δ9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer’s disease
Núria Sánchez-Fernández, Laura Gómez-Acero, Anna Castañé, et al.
Research Square (Research Square) (2024)
Open Access
Núria Sánchez-Fernández, Laura Gómez-Acero, Anna Castañé, et al.
Research Square (Research Square) (2024)
Open Access
Diagnostic information in GP referral letters to a memory clinic: a retrospective cohort study
Demi Ronner, Dorien L. Oostra, Jurgen A.H.R. Claassen, et al.
BJGP Open (2024), pp. BJGPO.2024.0065-BJGPO.2024.0065
Open Access
Demi Ronner, Dorien L. Oostra, Jurgen A.H.R. Claassen, et al.
BJGP Open (2024), pp. BJGPO.2024.0065-BJGPO.2024.0065
Open Access
Less Is More With Medication Use, But More Is Better When It Comes to Team Care: Embracing Interdisciplinary Team Care & Welcoming a New Section Editor
Donna M. Fick
Journal of Gerontological Nursing (2023) Vol. 49, Iss. 12, pp. 3-4
Closed Access
Donna M. Fick
Journal of Gerontological Nursing (2023) Vol. 49, Iss. 12, pp. 3-4
Closed Access
